Follow us on Twitter
twitter icon@FreshPatents


Hla patents

      

This page is updated frequently with new Hla-related patent applications.




 Methods and compositions for treatment of chlamydial infection and related diseases and disorders patent thumbnailMethods and compositions for treatment of chlamydial infection and related diseases and disorders
The present invention provides compositions and methods of use in the treatment/prevention of chlamydial infection and/or diseases and disorders associated with chlamydial infection in a subject.. .
Wake Forest University Health Sciences


 Chlamydia  antigens and uses thereof patent thumbnailChlamydia antigens and uses thereof
The present invention provides novel chlamydia antigens, nucleic acids encoding the antigens, and immunogenic compositions including the antigens. The present invention further provides methods of using the antigens to elicit immune responses (e.g., t cell-mediated and/or b cell-mediated immune responses).
Genocea Biosciences, Inc.


 Chlamydia vaccine patent thumbnailChlamydia vaccine
Compositions and methods for the treatment of chlamydial infection are disclosed. The compositions provided include polypeptides that contain at least one antigenic portion of a chlamydia antigen and dna sequences encoding such polypeptides.
Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services


 Hjurp peptides and vaccines including the same patent thumbnailHjurp peptides and vaccines including the same
Isolated peptides derived from seq id no: 50 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic t cell inducibility of the original sequence.
Oncotherapy Science, Inc.


 Immunogenic compositions patent thumbnailImmunogenic compositions
The present invention provides compositions comprising a chlamydial major outer membrane protein (referenced herein as “momp”), from at least one chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product e6020 having cas number 287180-63-6. The composition may further comprise at least one carrier system (e.g., emulsion, mineral particle).
Sanofi Pasteur, S.a.


 Assay for chlamydia trachomatis by amplification and detection of chlamydia trachomatis pmpa gene patent thumbnailAssay for chlamydia trachomatis by amplification and detection of chlamydia trachomatis pmpa gene
A region of the chlamydia trachomatis pmpa gene has been identified which is useful for performing amplification assays to determine specifically whether c. Trachomatis is present in the sample being tested.
Becton, Dickinson And Company


 Type iii secretion injectisome proteins for treatment and prevention of chlamydial infections patent thumbnailType iii secretion injectisome proteins for treatment and prevention of chlamydial infections
Cpn0803, copb (cpn0809) and copd (cpn0808) proteins and homologues thereof are shown to induce an immune response that is protective against a live challenge with chlamydia. Methods and uses of cpn0803 or fragments or epitopes thereof alone or together with copb and/or copd or fragments or epitopes thereof for treating or preventing chlamydial infection in a subject in need thereof are provided..
Mcmaster University


 Neil3 peptides and vaccines including the same patent thumbnailNeil3 peptides and vaccines including the same
The present invention provides isolated peptides or the fragments derived from seq id no: 45, which bind to an hla antigen and induce cytotoxic t lymphocytes (ctl). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences.
Oncotherapy Science, Inc.


 Quinazolinone derivatives for use in the treatment of chlamydiales infections patent thumbnailQuinazolinone derivatives for use in the treatment of chlamydiales infections
Wherein, r1, r2, r3, r4 and p are as defined in claim 1.. .

 Benzodiazepine derivatives for use in the treatment of chlamydiales infections patent thumbnailBenzodiazepine derivatives for use in the treatment of chlamydiales infections
Wherein r1, r2, r3 and ar are as defined in claim 1.. .

Adamantane or pinene derivatives for use in the treatment of chlamydiales infections

Wherein w, l1, l2 and ar are as defined in claim 1.. .

Nucleic acid probe with single fluorophore label bound to internal cytosine for use in loop mediated isothermal amplification

The disclosure relates to novel probes for use in lamp detection methods. The probes contain a single fluorophore label bound to an internal cytosine residue of the probe.
Mast Group Limited

Methods of detecting chlamydia and gonorrhea and of screening for infection/inflammation based on genomic copy number

Compositions and methods for detecting chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) are provided. The present invention also provides methods and compositions for screening for infection/inflammation based on genomic copy number.
Cepheid

Methods of detecting antibodies specific for denatured hla antigens

The invention is directed to methods of screening for hla antibodies comprising detecting antibodies specific for native hla antigens and denatured hla antigens. The invention also provides for methods of removing antibodies specific for denatured hla antigens or antibodies specific for native hla antigens from a serum sample.
One Lambda, Inc.

Compositions and methods for providing hematopoietic function

The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting a pool of expanded human cord blood stem/progenitor cell samples for administration to the patient, wherein the samples in the pool collectively do not mismatch the patient at more than 2 of the hla antigens or alleles typed in the patient; and administering the selected pool of expanded human cord blood stem/progenitor cell samples to the patient. Methods for obtaining the pools of expanded human cord blood stem/progenitor cell samples, banks of frozen pools of expanded human umbilical cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein..
Fred Hutchinson Cancer Research Center

Chlamydia antigens

The invention provides chlamydia antigens for use in the treatment, prevention and/or diagnosis of chlamydia infection. In particular, the invention provides antigens ct733, ct153, ct601, ct279, ct443, ct372, ct456, ct381, ct255, ct341, ct716, ct745, ct387, ct812, ct869, ct166, ct175, ct163, ct214, ct721, ct127, ct043, ct823 and/or ct600 from c.
Glaxosmithkline Biologicals Sa

Compositions for and methods of identifying antigens

Replicable libraries having discrete members in defined locations for screening for antigens to a pathogenic organism are provided. Also provided are methods for using such libraries as well as a specific antigen, ct788, which induces t-cell activation during a chlamydia infection..
President And Fellows Of Harvard College

Omv vaccines

The invention is in the field of outer membrane vesicles (omv) and their uses. More particularly the present invention provides omv obtained from a bacterium being an ompa mutant and/or a mutant in one or more components of the tolpal complex and presenting a heterologous antigen on its surface.
Novartis Ag

Chlamydia antigen compositions and uses thereof

The present invention provides in part fusion proteins derived from chlamydia spp. The present invention also provides in part methods for treating or preventing chlamydia infection using the fusion proteins..
The University Of British Columbia

Tumor vaccine

The invention relates to the fields of medicine, immunology, and oncology. More specifically, the invention relates to methods and compositions for inducing an immune response against a tumor in an animal subject.
University Of Miami

Polynucleotides for the amplification and detection of chlamydia trachomatis and neisseria gonorrhoeae

Polynucleotides useful for detecting chlamydia trachomatis and/or neisseria gonorrhoeae in a test sample, kits, a nucleic acid amplification method and detection method including the same.. .
Abbott Molecular Inc.

P2x7 modulators

The present invention is directed to a compound of formula (i) or (ia) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) or (ia) and methods comprising administering of compounds of formula (i) or (ia) for treating rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv

P2x7 modulators

The present invention is directed to a compound of formula (i) formula (i) the invention also relates to pharmaceutical compositions comprising compounds of formula (i) and methods comprising administering to a subject at least one compound selected from compounds of formula (i) for treating diseases mediated by p2x7 receptor activity, such as rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, parkinson's disease, schizophrenia, alzheimer's disease, huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, polycystic kidney disease, glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, amyotrophic lateral sclerosis, chaga's disease, chlamydia, neuroblastoma, tuberculosis, and migraine.. .
Janssen Pharmaceutica Nv

Attenuated chlamydia vaccine

The invention provides vectors, attenuated pathogens, compositions, methods, and kits for use in preventing or treating infection by an infectious pathogen, especially chlamydia trachomatis. The vectors comprise the plasmid encoded ppg genes from chlamydia, ppg1, ppg2, ppg3, ppg5, ppg6, ppg7 and/or ppg8, but lack ppg4, a regulator of virulence associated genes.
The United States Of America,as Represented By The Secretary, Department Of Health & Human Services

Primer and probe sequences for detecting chlamydia trachomatis

The present invention relates to primers and probes that can be used in various assays to detect a new strain of chlamydia trachomatis. The invention further provides for the simultaneous detection of other diseases, especially neisseria gonorrhoeae..
Abbott Molecular Inc.

Methods of detecting chlamydia and gonorrhea and of screening for infection/inflammation based on genomic copy number

Compositions and methods for detecting chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) are provided. The present invention also provides methods and compositions for screening for infection/inflammation based on genomic copy number.
Cepheid

Tomm34 peptides and vaccines including the same

The present invention provides isolated peptides or the fragments derived from seq id no: 42, which bind to an hla antigen and induce cytotoxic t lymphocytes (ctl). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences.
Oncotherapy Science, Inc.

Emp2 antibodies and their therapeutic uses

The present invention provides methods and compositions useful in the treatment or prevention of chlamydia infections and cancer. The methods and compositions inhibit the entry of chlamydia into a host cell expressing emp2 by interfering with the interaction between the chlamydia and emp2.
The Regents Of The University Of California

Method and its compositions for detection of nucleic acid target from biological samples and body fluids

Current invention is directed for rapid sample pretreatment method that allows highly sensitive and specific detection of target nucleic acid (eg human genomic dna, human pathogen genomic dna, human non-pathogen genomic dna) by amplification directly from crude unpurified biological samples lysates (eg human urine, saliva, blood, urethra and cervical swabs and other samples containing biological material). Invention is focused on the description of the biological sample pretreatment method that enables fast release of the genomic material from human and pathogen cells, components of what are compatible with the following nucleic acid amplification method.
Selfdiagnostics OÜ

Neil3 peptides and vaccines including the same

The present invention provides isolated peptides or the fragments derived from seq id no: 45, which bind to an hla antigen and induce cytotoxic t lymphocytes (ctl). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences.

Mutant forms of chlamydia htra

An immunogenic chlamydia htra protein, which has one or more mutations relative to wild-type chlamydia htra that result in a reduced or eliminated protease activity relative to the protease activity of wild-type chlamydia htra. Preferably, it is the serine protease activity that is reduced or eliminated..
Novartis Ag

Personalized cancer vaccines and adoptive immune cell therapies

Cancer antigens containing mutations in an expressed gene of cancer cells from a cancer patient are identified. Sequences from cancer cells obtained using a parallel sequencing platform are selected by comparing to the patient's normal genes or to normal genes from an hla-matched individual.
Persimmune, Inc.

Real-time pcr for the detection of pathogens

Disclosed herein are methods for detecting presence of one or more of acinetobacter baumannii, pseudomonas aeruginosa, klebsiella pneumoniae, toxoplasma gondii, moraxella catarrhalis, escherichia coli, shigella, staphylococcus aureus, pneumocystis jirovecii, chlamydia trachomatis, ureaplasma urealyticum, ureaplasma parvum, ureaplasma spp., bartonella spp., streptococcus agalactiae, and neisseria meningitidis nucleic acids in a sample, such as a biological sample obtained from a subject, or an environmental sample. This disclosure also provides probes, primers, and kits for detecting one or more of acinetobacter baumannii, pseudomonas aeruginosa, klebsiella pneumoniae, toxoplasma gondii, moraxella catarrhalis, escherichia coli, shigella, staphylococcus aureus, pneumocystis jirovecii, chlamydia trachomatis, ureaplasma urealyticum, ureaplasma parvum, ureaplasma spp., bartonella spp., streptococcus agalactiae, and neisseria meningitidis in a sample..
The Government Of The Usa As Represented By The Secretary Of The Dept Of Health And Human Services

Methods and compositions for treatment of chlamydial infection and related diseases and disorders

The present invention provides compositions and methods of use in the treatment/prevention of chlamydial infection and/or diseases and disorders associated with chlamydial infection in a subject.. .
Wake Forest University Health Sciences

Method of intracellular infectious agent detection in sperm cells

The present invention describes a method for investigating the presence of chlamydia, viruses and other infectious agents in spermatozoa, with the use of immunofluorescence in combination with flow cytometry. This method is used for the intracellular detection of microorganisms within sperm cells through the use of a dna easing procedure, as well as for the detection of microorganisms adherent to the surface of spermatozoa..

Compositions and methods for immunodominant antigens

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (burkholderia pseudomallei, borrelia burgdorferi, brucella melitensis, chlamydia muridarum, coxiella burnetii, francisella tularensis, human herpes virus 1 and 2, mycobacterium tuberculosis, plasmodium falciparum, and vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter..
Immport Therapeutics, Inc.

Chlamydia antigen compositions and uses thereof

The present invention provides in part peptides and polypeptides derived from chlamydia app. The present invention also provides in part methods for treating, preventing or diagnosing chlamydia infection using the peptides and polypeptides..
The University Of British Columbia





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Hla for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Hla with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.1878

file did exist - 2391

0 - 1 - 50